Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients

Untreated Adult Acute Myeloid Leukemia Clinical Trial

Official title:

The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01633099
• Other study ID #: DACOGENAML2003
• Status: Unknown status
• Phase: Phase 3
• First received: June 24, 2012
• Last updated: July 4, 2012
• Start date: May 2012
• Est. completion date: July 2016

Study information

• Verified date: July 2012
• Source: Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to confirm the safety and the therapeutic effect of Decitabine in the treatment of elderly Acute Myeloid Leukemia (AML) patients.

Description:

The outcome of the elderly AML patients is very poor. No obvious progress was achieved in this field. Decitabine is a kind of specific DNA methylation shift enzyme inhibitor. It can reverse the DNA methylation and induce the differentiation and apoptosis of the tumor cells. Recent studies about decitabine in the treatment for elderly AML patients had achieved inspiring results and indicated that low dose decitabine maybe a good choice for elderly AML patients. So in this research the investigators plan to evaluate the safety and the therapeutic effect of decitabine in the treatment of elderly AML patients.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 46
• Est. completion date: July 2016
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of acute myeloid leukemia.De novo or secondary AML.

2. Age >= 60years,female and male.

3. Before the enrollment,WBC < 40×10E9/L,Plt > 20×10E9/L(Hydroxyurea is permitted.)

4. In 2 weeks before the enrollment,total bilirubin < 1.5×ULN,ALT < 2.5×ULN;GGT < 2.5×ULN ,Scr < 2.0×ULN or creatinine clearance rate = 50 ml/min(Cockroft-Gault).

5. Before the enrollment,patients must be free from the toxicity caused by the former treatment.Received no chemotherapy in the last 4 weeks and no nitrosourea in the last 6 weeks.

6. Contraception must be taken to avoid pregnancy during the study.

7. ECOG 0,1, or 2, predicted lifetime longer than 12 weeks.

8. Patients must sign the informed consent prior to any study related screening procedures being performed.

Exclusion Criteria:

1. Acute promyelocytic leukemia.

2. Chromosome and genetic abnormalities related with t(8; 21)?inv(16)?t(15; 17).

3. Central nervous system leukemia.

4. Bone marrow dry tap.

5. Patients received stem cell transplantation or chemotherapy containing azacitidine,cytarabine or decitabine in last one year, radiation therapy in last 14 days,lenalidomide in 30 days before included.

6. Patients suffered from autoimmune hemolytic anemia or immune thrombocytopenia.

7. Patients suffered from non-leukemia related comorbidities that will cause dysfunction of organs.

8. Patients suffered from unstable angina or (NYHA)3/4 Congestive heart failure.

9. Patients suffered from chronic respiratory disease and needed continued oxygen.

10. Other active malignancy.

11. Active HBV,HCV or AIDS patients.

12. Uncontrolled virus or bacterium infection.

13. The investigator believe that patients who are not suitable for this trial.

14. Severe mental or body disorders which will interfere the research such as uncontrolled heart,lung diseases,diabetes,etc.

15. Allergic to decitabine or its accessory.

16. Patients received other researches in last 30 days.

17. Without contraception.

18. Complications causing organ dysfunction which are not caused by AML.

Related Conditions & MeSH terms

• Drug Safety
• Effect of Drugs
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Untreated Adult Acute Myeloid Leukemia

Intervention

Drug:
• Decitabine
Number of Cycles: 4 cycles. Dose and drug delivery(decitabine): The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells=5%, the following cycle is the same as the 1st cycle. If bone marrow blast cells<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle. If Grade 4 neutropenia(<0.5×10E9/L)come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia(<0.5×10E9/L)come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle).

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Jianxiang Wang	Xian-Janssen Pharmaceutical Ltd.

References & Publications (1)

Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007 Mar 15;109(6):1114-24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete response rate after induction chemotherapy with decitabine		21 days after the induction chemotherapy
Primary	Overall survival rate		Up to 46 months after inclusion
Primary	Event free survival rate		Up to 46 months after inclusion
Primary	Relapse free survival rate		Up to 46 months after inclusion
Secondary	Adverse events of decitabine for elderly AML patients		Up to 46 months
Secondary	Weight of elderly AML patients		Up to 46 months
Secondary	ECOG(Eastern Cooperative Oncology Group) score for elderly AML patients		Up to 46 months
Secondary	Physical examination of decitabine for elderly AML patients		Up to 46 months
Secondary	Blood pressure of elderly AML patients		Up to 46 months
Secondary	Respiratory rate of elderly AML patients		Up to 46 months
Secondary	Heart rate of elderly AML patients		Up to 46 months
Secondary	Body temperature of elderly AML patients		Up to 46 months
Secondary	ECG of elderly AML patients		Up to 46 months
Secondary	Bone marrow condition of elderly AML patients		Up to 46 months

External Links

•   We do not have a protocol's home page. This website is our hospital's home page and introduces some information of our hospital.